| Literature DB >> 27575253 |
Brendan Epstein1, Menna Jones2, Rodrigo Hamede2, Sarah Hendricks3, Hamish McCallum4, Elizabeth P Murchison5, Barbara Schönfeld2, Cody Wiench3, Paul Hohenlohe3, Andrew Storfer1.
Abstract
Although cancer rarely acts as an infectious disease, a recently emerged transmissible cancer in Tasmanian devils (Sarcophilus harrisii) is virtually 100% fatal. Devil facial tumour disease (DFTD) has swept across nearly the entire species' range, resulting in localized declines exceeding 90% and an overall species decline of more than 80% in less than 20 years. Despite epidemiological models that predict extinction, populations in long-diseased sites persist. Here we report rare genomic evidence of a rapid, parallel evolutionary response to strong selection imposed by a wildlife disease. We identify two genomic regions that contain genes related to immune function or cancer risk in humans that exhibit concordant signatures of selection across three populations. DFTD spreads between hosts by suppressing and evading the immune system, and our results suggest that hosts are evolving immune-modulated resistance that could aid in species persistence in the face of this devastating disease.Entities:
Mesh:
Year: 2016 PMID: 27575253 PMCID: PMC5013612 DOI: 10.1038/ncomms12684
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919
Figure 1Sample collection sites in Tasmania.
The three focal populations are labelled and marked with large magenta circles; smaller grey circles mark additional sampling sites, which were sampled across the entire geographic range to capture a species-wide representation of genetic diversity. The magenta lines indicate the approximate location of the disease front67 in 2000, 2005, 2010 and 2015.
Figure 2Selection test statistics for each SNP in the candidate regions and approximately 4 Mb on either side.
Panels (a–e) are for chr. 2 and panels (f–j) are for chr. 3. The scaffolds, positions and genes (grey boxes) are shown in panels a and f, the positions are given in Mb from the start of each scaffold, which are marked with light grey vertical lines and a label (GL841593, and so on). Below those panels, values of three statistics are shown for each filter-passing SNP: (b,g) allele frequency change; (c,h) rsb; and (d,i) point estimates of the fitness advantage of the increasing allele. Panels e and j show the trajectory of allele frequency change over time; for clarity, we only show SNPs with relatively high genotyping rates and the x axis is time since detection of DFTD (first detection of DFTD is marked with a vertical line). SNPs are colour-coded by population, the candidate region is marked with a dark grey box and the names of candidate genes are labelled. Due to multiple steps of data filtering, each population has a different set of SNPs.
The seven candidate genes found in or closest to regions with concordant signatures of selection.
| Ensembl ID | Chr | Scaffold | Human orthologue ensembl ID | Description | Putative function or phenotype |
|---|---|---|---|---|---|
| ENSSHAG00000008028 | 3 | GL849657 | ENSG00000110395 | Cbl proto-oncogene, E3 ubiquitin protein ligase ( | Cancer risk and immune reaction to cancer |
| ENSSHAG00000007967 | 3 | GL849657 | ENSG00000076706 | Melanoma cell adhesion molecule ( | Immune regulation |
| ENSSHAG00000007202 | 3 | GL849657 | ENSG00000223953 | C1q and tumour necrosis factor-related protein 5 ( | Cell adhesion, retinal degeneration |
| ENSSHAG00000006515 | 3 | GL849657 | ENSG00000036672 | Ubiquitin-specific peptidase 2 ( | Cell-cycle regulation |
| ENSSHAG00000005936 | 3 | GL849657 | ENSG00000154096 | Thy-1 cell surface antigen ( | Immune regulation, cell-cycle regulation |
| ENSSHAG00000007088 | 3 | GL849657 | ENSG00000235718, ENSG00000259159 | Uncharacterized protein | Unknown; homology to membrane-frizzled proteins |
| ENSSHAG00000018867 | 2 | GL841593 | ENSG00000113851 | Cereblon ( | Myeloma therapy target; limb and brain development |